Avance Clinical’s Oncology Center of Excellence is Re-shaping Early Phase Cancer Research

In this video series, George Peoples, MD, FACS, Executive Medical Director of Avance Clinical’s Oncology Center of Excellence, reveals how the CRO is bringing together top scientific and operational minds to accelerate innovation in oncology drug development.

With the Oncology Center of Excellence’s deep therapeutic expertise, APAC-based Early Phase capabilities, biotechs gain access to seamless early oncology development, where speed, insight, and precision matter most.

What is the Oncology Center of Excellence

Dr. George Peoples, surgical oncologist and Executive Medical Director, shares the story of his career in cancer care and immuno-oncology drug development to founding LumaBridge — a boutique oncology CRO which was acquired by Avance Clinical in 2026. In this video, Dr. Peoples explains how the Center brings together subject matter experts in clinical care, drug development, and trial execution.

Learn how early engagement with biotech companies helps refine clinical trial strategies, avoid common pitfalls, and navigate the complexities of oncology drug development.

How the Oncology Center of Excellence Engages Biotechs

In this video, Dr. George Peoples explains how Avance Clinical’s Oncology Center of Excellence partners with biotech companies to support their drug development journey. Whether a sponsor arrives with a well-defined plan or is just getting started, the team provides thoughtful, expert guidance on clinical development strategy.

Why Therapeutic Experience Matters

With dozens of new oncology drugs approved by the FDA last year alone, the cancer treatment landscape is moving at an unprecedented pace. In this video, Dr. George Peoples shares why deep therapeutic expertise is essential when developing new oncology drugs, and how biotech companies can navigate this rapidly shifting field.

Why Choose Avance Clinical’s Oncology Center of Excellence

The merger of LumaBridge’s oncology expertise with Avance Clinical’s strength in Phase 1 studies has created something powerful: the Oncology Center of Excellence. In this video, Dr. George Peoples discusses how this combination enables seamless early clinical development of novel assets, exactly what biotech companies need in today’s challenging funding environment.

Partner With Avance Clinical

Avance Clinical’s Oncology Center of Excellence gives emerging biotechs a strategic edge through:

  • Early Engagement & Expert Guidance – Connect with oncology specialists to shape more efficient development pathways.
  • Deep Insight into Novel Mechanisms of Action – Engage in thoughtful scientific discussions that sharpen your program’s potential.
  • Patient Population Identification & Optimization – Leverage expertise to pinpoint and refine the most relevant patient groups.
  • End-to-End Clinical Development Strategy – Receive comprehensive guidance from preclinical considerations through trial execution with a scientific and operational team with deep oncology experience.
  • Study Designs Aligned with FDA Expectations – Develop protocols, including dosing strategies, built to meet regulatory standards from day one.
  • Help Navigating a Constantly Evolving Oncology Landscape – Stay ahead with experts who understand today’s therapies, tomorrow’s innovations, and how your treatment fits within the competitive landscape.

Whether you are an early-stage startup or a growing biotech, Avance Clinical gives you direct access to oncology specialists who understand the complexities of modern cancer development, from scientific nuance to regulatory demands to operational execution.

We look forward to connecting with you and discussing your upcoming oncology clinical trial or drug development journey, and offering a smarter, more efficient way to move your oncology program forward.